Scientists have revealed details of the discovery of a new cancer drug that could be used to treat a range of cancer types, including some
Scientists at Sanford Burnham Prebys Medical Discovery Institute have created a next-generation drug called Ciapavir (SBI-0953294) that is effective at reactivating dormant human immunodeficiency virus (HIV). The
The first patients in each of two early-stage clinical trials testing CRISPR-based treatments for inherited blood disorders have been symptom free for several months with
A clinical trial of a gene therapy for Duchenne muscular dystrophy has been halted after a patient suffered serious side effects following treatment, Reuters reports
The failure of drugs that seemed promising in laboratory tests to prove themselves in human testing is an all-too-common occurrence, dashing hopes and costing billions
When I visited Ricaurte, Colombia, in 2016, I was surrounded by men with long faces and prominent ears. As we spoke, they would ask repetitive
Gut bacteria harbor enzymes and pump out other molecules that can influence how medications are activated or broken down. One example is the Parkinson’s drug
A treatment regimen for extensively drug-resistant tuberculosis could help stem the growing problem of hard-to-treat TB infections in developing countries, according to the Associated Press.
Modifying levels of vasopressin, a hormone related to oxytocin that is involved in the regulation of mammalian social behavior, could enhance social function in people
In October, researchers at Kyoto University transplanted cells generated from induced pluripotent stem cells into the brain of a man with Parkinson’s disease, the scientists
A combination of chemotherapy and immunotherapy slows disease progression in patients with metastatic triple-negative breast cancer, according to results published Saturday (October 20) in the
The European Commission has approved the use of Novartis’s tisagenlecleucel (Kymriah) and Gilead’s axicabtagene ciloleucel (Yescarta), two chimeric antigen receptor T cell (CAR T) therapies,
Due to advances in rare-disease research and individualized cell and gene therapies, there has been a recent crop of treatments approved by regulatory agencies not
At the annual American Society of Clinical Oncology meeting last June, Bristol-Myers Squibb (BMS) researchers presented data on a cohort of patients not responding to
At the annual American Society of Clinical Oncology meeting last June, Bristol-Myers Squibb (BMS) researchers presented data on a cohort of patients not responding to
Studying scorpions comes with its share of danger, as biologist Bryan Fry of the University of Queensland knows all too well. On a 2009 trip
Several haematological malignancies, including multiple myeloma (MM) and acute myeloid leukaemia (AML), have well-defined precursor states that precede the development of overt cancer. MM is
Researchers report promising results in a Phase 1 trial testing a new cell therapy using chimeric antigen receptor (CAR) T-cell technology on patients suffering from
On a fall day in 2015 at Sunnybrook hospital in Toronto, a dozen people huddled in a small room peering at a computer screen. They
Alnylam Pharmaceuticals is reporting positive results from a clinical trial using patisiran—an RNA interference (RNAi) drug—to treat patients suffering from hereditary amyloidosis with polyneuropathy, a
MicroRNAs (miRNAs) regulate gene expression by inducing mRNA decay. But miRNAs can be regulated through other RNAs and DNA that bind and sequester them without
Armed with a modified version of CRISPR-Cas9, scientists have removed nucleotide repeats from RNA in vitro that are known to cause diseases, namely, Huntington’s, ALS,
A popular chemogenetic technique for controlling cells does not operate in vivo in the way scientists had assumed. Reporting in Science yesterday (August 3), researchers
The Ebola virus glycoprotein spike (white) bound by antibody fragments of the broadly neutralizing antibodies ADI-15878 (purple), ADI-15946 (blue), and ADI-16061 (green). Footprints of these
Cold Spring Harbor Laboratory molecular geneticist Adrian Krainer was at a National Institutes of Health workshop in 1999 when he first learned about the crippling
Created by ePubSystems. Contact Us for similar site for your university or institute.